NKT AS (NRKBY) reports improved operational EBITDA margin of 15.7% and raises full-year 2026 EBITDA outlook to EUR400-430 million despite a 9% organic revenue decline.

NKT AS (NRKBF) reports strong order intake and operational improvements, while navigating revenue declines and cost pressures.

If you are wondering whether NKT at DKK 819.5 is still offering value or if most of the upside is already reflected in the price, you are asking the right question for this stock. The share price return sits at 3.5% over the last 7 days, with a 0.8% decline over 30 days, a 0.5% decline year to date, and a 71.0% gain over 1 year that adds important context to any valuation view. Recent news flow has focused on NKT's role within the capital goods sector, including its exposure to large scale...

NKT AS (NRKBF) reports strong annual results despite Q4 revenue decline, with a focus on strategic investments and a promising high-voltage order backlog.

NKT AS (NRKBF) reports robust financial performance with record operational EBITDA and ambitious growth strategy, despite facing cash flow and margin pressures.

For investors keeping an eye on NKT (CPSE:NKT), the stock’s latest rally might seem sudden but is drawing fresh attention for good reason. While there hasn’t been a specific headline or event sparking this move, shifts like these often leave market watchers wondering whether the stock is signaling a change below the surface or merely catching a wave of renewed interest. In such a moment, it pays to pause and ask what could be driving sentiment, and does it make sense from a value...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.